Clinical Trial Update: Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery [Phase 3]

View source ↗

Summary

Phase 3 confirmatory study of 17P vs vehicle for prevention of preterm birth in women with prior spontaneous preterm delivery completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• 17P (17-hydroxyprogesterone caproate) (17-hydroxyprogesterone caproate)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Preterm Birth | Phase 3 | Status: COMPLETED | Results posted: 2021-01-28